Clinical Trials Browser

Completed × apatinib × Breast × Clear all

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Phase 1 Completed

Triple Negative Breast Neoplasms

NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Phase 1 Completed

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03254654 2022-04-20

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Phase 2 Completed

Advanced Triple-Negative Breast Cancer

NCT03243838 2022-02-02

LANCET

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT02878057 2021-01-27

Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)

Phase 2 Completed

30 enrolled 12 charts

Breast Neoplasms

NCT03394287 2020-10-23

A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC

Phase 2 Completed

Breast Neoplasms

NCT03384511 2018-02-20

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Phase 4 Completed

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT01176669 2015-09-09

Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01653561 2013-12-03

A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms